Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-?
- 27 August 1999
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 82 (5) , 727-736
- https://doi.org/10.1002/(sici)1097-0215(19990827)82:5<727::aid-ijc17>3.0.co;2-e
Abstract
The expression and functionality of the Fas receptor (CD95/APO-1) play an important role for the maintenance of tissue homeostasis. Various types of tumor cells have been shown to escape immune recognition by constitutive resistance to CD95-mediated apoptosis. Furthermore, several apoptosis-related proteins have been reported to influence CD95 sensitivity. We tested an unselected panel of 11 melanoma cell lines for sensitivity to CD95 and the corresponding expression of CD95, CD95L, bcl-2, bcl-x, bcl-xS, bax and FLIP proteins. Despite detection of CD95 cell-surface expression in 9 out of the 11 cell lines tested, only 3 melanoma cell lines were sensitive to anti-CD95-MAb-induced cell death. Apoptosis-related proteins CD95L, bcl-2, bcl-x, bcl-xS and bax were found to be heterogenously expressed in different melanoma cell lines tested. The susceptibility of melanoma cells to anti-CD95-MAb-mediated apoptosis was associated with low protein expression of both bcl-2 and bcl-x. The level of CD95 cell-surface expression in melanoma cells was no indicator for CD95 sensitivity. Furthermore, FLIP protein was detectable in 7 out of the 11 cell lines, but showed no correlation to CD95 sensitivity. Certain cytokines have been described as modulating the susceptibility of tumor cells to CD95-induced cell death. Since IFN-α was proved to be clinically efficient in melanoma therapy, we tested whether interferons have the ability to induce sensitivity to CD95 in primarily resistant melanoma cell lines. Here we show that IFN-γ, but not IFN-α, is able to increase the susceptibility of sensitive cell lines and to induce CD95 sensitivity in resistant melanoma cell lines, accompanied by up-regulation of the protein expression level of CD95 and/or bcl-xS. Int. J. Cancer 82:727–736, 1999.Keywords
This publication has 20 references indexed in Scilit:
- Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide.Journal of Clinical Investigation, 1997
- Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutantsEuropean Journal of Immunology, 1997
- Fas/APO-1-Mediated Apoptosis of Human Renal Cell CarcinomaBiochemical and Biophysical Research Communications, 1996
- Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune EscapeScience, 1996
- Bcl-2 expression in malignant melanoma and its prognostic significanceEuropean Journal of Surgical Oncology, 1996
- Interferons in melanomaCurrent Opinion in Oncology, 1996
- Induction of apoptotic cell death in non‐melanoma skin cancer by interferon‐αInternational Journal of Cancer, 1995
- Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines.Journal of Clinical Investigation, 1994
- bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell deathCell, 1993
- Monoclonal Antibody-Mediated Tumor Regression by Induction of ApoptosisScience, 1989